Ibritumomab tiuxetan Clinical Trials

• Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
  ClinicalTrials.gov Identifier: NCT00493454 - Active, not recruiting
  Lymphoma
  
• Ibritumomab Tiuxetan + Rituximab Maintenance
  ClinicalTrials.gov Identifier: NCT00582166 - Recruiting
  Non-Hodgkin's Lymphoma
  
• Ibritumomab Tiuxetan for Early Stage Indolent Lymphomas
  ClinicalTrials.gov Identifier: NCT00493467 - Recruiting
  Lymphoma
  
• Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
  ClinicalTrials.gov Identifier: NCT00058422 - Recruiting
  noncontiguous stage II adult diffuse large cell lymphoma; stage III adult diffuse large cell lymphoma; stage IV adult diffuse large cell lymphoma
  
• Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00193440 - Active, not recruiting
  Non-Hodgkins Lymphoma
  
• Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
  ClinicalTrials.gov Identifier: NCT00562978 - Active, not recruiting
  Lymphoma
  
• Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, and Radiation Therapy in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Relapsed Or Refractory Non-Hodgkin''s Lymphoma
  ClinicalTrials.gov Identifier: NCT00119392 - Recruiting
  adult non-Hodgkin''s lymphoma
  
• CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Treatment
  ClinicalTrials.gov Identifier: NCT00438880 - Active, not recruiting
  Lymphoma
  
• Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00110149 - Recruiting
  grade 1 follicular lymphoma; grade 2 follicular lymphoma; marginal zone lymphoma; Small Lymphocytic Lymphoma
  
• Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00416312 - Recruiting
  Lymphoma
  
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
  ClinicalTrials.gov Identifier: NCT00453102 - Recruiting
  Lymphoma
  
• Motexafin Gadolinium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage II, Stage III, or Stage IV Relapsed or Refractory Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00089284 - Recruiting
  adult non-Hodgkin's lymphoma; indolent or aggressive adult non-Hodgkin's lymphoma
  
• Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia
  ClinicalTrials.gov Identifier: NCT00060294 - Completed
  Waldenstrom's Macroglobulinemia
  
• Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00372905 - Recruiting
  Lymphoma
  
• Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00397800 - Recruiting
  Lymphoma
  
• Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00005592 - Active, not recruiting
  recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent adult diffuse small cleaved cell lymphoma; ...
  
• Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Lymphoma
  ClinicalTrials.gov Identifier: NCT00088881 - Recruiting
  stage I adult diffuse large cell lymphoma; stage II adult diffuse large cell lymphoma
  
• Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00334438 - Recruiting
  Lymphoma
  
• Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
  ClinicalTrials.gov Identifier: NCT00185393 - Active, not recruiting
  Non Hodgkin Lymphoma
  
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00073957 - Recruiting
  recurrent adult diffuse large cell lymphoma; recurrent adult immunoblastic large cell lymphoma; anaplastic large cell lymphoma
  
• Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
  ClinicalTrials.gov Identifier: NCT00070447 - Active, not recruiting
  contiguous stage II mantle cell lymphoma; noncontiguous stage II mantle cell lymphoma; stage III mantle cell lymphoma; stage IV mantle cell lymphoma
  
• Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
  ClinicalTrials.gov Identifier: NCT00392691 - Recruiting
  Lymphoma
  
• Radioimmunotherapy With 90Y-Ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma
  ClinicalTrials.gov Identifier: NCT00302757 - Recruiting
  Non-Hodgkin Lymphoma
  
• Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma
  ClinicalTrials.gov Identifier: NCT00577278 - Recruiting
  Graft Versus Host Disease; Leukemia; Lymphoma
  
• Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma
  ClinicalTrials.gov Identifier: NCT00082836 - Completed
  primary central nervous system lymphoma
  
• Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00477815 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00070018 - Recruiting
  adult Burkitt's lymphoma; adult diffuse large cell lymphoma; adult non-Hodgkin's lymphoma; anaplastic large cell lymphoma; Mantle Cell Lymphoma
  
• 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
  ClinicalTrials.gov Identifier: NCT00186589 - Completed
  Lymphoma, Non-Hodgkin
  
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00062114 - Completed
  recurrent adult diffuse large cell lymphoma; recurrent adult diffuse mixed cell lymphoma; recurrent adult immunoblastic large cell lymphoma
  
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
  ClinicalTrials.gov Identifier: NCT00064246 - Completed
  adult Burkitt's lymphoma; adult diffuse large cell lymphoma; indolent, adult non-Hodgkin's lymphoma; post-transplant lymphoproliferative disorder
  
• Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
  ClinicalTrials.gov Identifier: NCT00036855 - Completed
  AIDS-Related Lymphoma; childhood large cell lymphoma; childhood lymphoblastic lymphoma; childhood small noncleaved cell lymphoma; ...
  
• Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00033423 - Active, not recruiting
  grade 1 follicular lymphoma; grade 2 follicular lymphoma; grade 3 follicular lymphoma; marginal zone lymphoma; Small Lymphocytic Lymphoma
  
• Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
  ClinicalTrials.gov Identifier: NCT00038623 - Active, not recruiting
  Lymphoma, Mantle-Cell
  
• Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00058292 - Active, not recruiting
  adult non-Hodgkin's lymphoma
  
• Comparative Trial between Bexxar and Zevalin
  ClinicalTrials.gov Identifier: NCT00078676 - Not yet recruiting
  Follicular Lymphoma; Diffuse Large Cell Lymphoma
  
• Monoclonal Antibody Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00017381 - Recruiting
  adult non-Hodgkin's lymphoma; indolent or aggressive adult non-Hodgkin's lymphoma
  
• Yttrium-90 Ibritumomab Tiuxetan (Zevalin) with BEAM in Relapsed Low Grade B-Cell Lymphoma
  ClinicalTrials.gov Identifier: NCT00138086 - Completed
  B Cell Lymphoma
  
• Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00012298 - Recruiting
  grade 1 follicular lymphoma; grade 2 follicular lymphoma; grade 3 follicular lymphoma; indolent, adult non-Hodgkin's lymphoma; marginal zone lymphoma; ...
  
• Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation
  ClinicalTrials.gov Identifier: NCT00031642 - Completed
  adult non-Hodgkin's lymphoma
  
• Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00057343 - Terminated
  Non-Hodgkin's Lymphoma